Cargando…

Eomesodermin is required for antitumor immunity mediated by 4-1BB-agonist immunotherapy

CD8(+) T cells in progressing tumors frequently fail to mount an effective antitumor response often in association with the expression of inhibitory receptors, including programmed cell death-1 (PD-1) and lymphocyte-activation gene 3 (Lag3). Using a lymphoma tumor model, we demonstrate that tumor-in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Song, Chang, Sadashivaiah, Kavitha, Furusawa, Aki, Davila, Eduardo, Tamada, Koji, Banerjee, Arnob
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Landes Bioscience 2014
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4002624/ https://www.ncbi.nlm.nih.gov/pubmed/24790793 http://dx.doi.org/10.4161/onci.27680

Ejemplares similares

STAT5 inhibition induces TRAIL/DR4 dependent apoptosis in peripheral T-cell lymphoma
por: Simpson, Haley M., et al.
Publicado: (2018)

Systemic 4-1BB activation induces a novel T cell phenotype driven by high expression of Eomesodermin
por: Curran, Michael A., et al.
Publicado: (2013)

Effector, Memory, and Dysfunctional CD8(+) T Cell Fates in the Antitumor Immune Response
por: Reiser, John, et al.
Publicado: (2016)

Nodal-Dependent Mesendoderm Specification Requires the Combinatorial Activities of FoxH1 and Eomesodermin
por: Slagle, Christopher E., et al.
Publicado: (2011)

Eomesodermin-expressing T-helper cells are essential for chronic neuroinflammation
por: Raveney, Ben J. E., et al.
Publicado: (2015)

T-bet and Eomesodermin in NK Cell Development, Maturation, and Function
por: Simonetta, Federico, et al.
Publicado: (2016)

Regulation of CD4 T Cell Responses by the Transcription Factor Eomesodermin
por: Dhume, Kunal, et al.
Publicado: (2022)

PET imaging to non-invasively study immune activation leading to antitumor responses with a 4-1BB agonistic antibody
por: Escuin-Ordinas, Helena, et al.
Publicado: (2013)

Global identification of Smad2 and Eomesodermin targets in zebrafish identifies a conserved transcriptional network in mesendoderm and a novel role for Eomesodermin in repression of ectodermal gene expression
por: Nelson, Andrew C, et al.
Publicado: (2014)

Concurrent Mutations in ATM and Genes Associated with Common γ Chain Signaling in Peripheral T Cell Lymphoma
por: Simpson, Haley M., et al.
Publicado: (2015)

Interleukin-4 Regulates Eomesodermin in CD8(+) T Cell Development and Differentiation
por: Carty, Shannon A., et al.
Publicado: (2014)

HHEX Promotes Hepatic-Lineage Specification through the Negative Regulation of Eomesodermin
por: Watanabe, Hitoshi, et al.
Publicado: (2014)

The emerging landscape of novel 4-1BB (CD137) agonistic drugs for cancer immunotherapy
por: Claus, Christina, et al.
Publicado: (2023)

4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity
por: Bartkowiak, Todd, et al.
Publicado: (2015)

The T-box Transcription Factor Eomesodermin Governs Hemogenic Competence of Yolk-Sac Mesodermal Progenitors
por: Harland, Luke T.G., et al.
Publicado: (2021)

Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcγR affinity
por: Qi, Xinyue, et al.
Publicado: (2019)

Eomesodermin of Atlantic Salmon: An Important Regulator of Cytolytic Gene and Interferon Gamma Expression in Spleen Lymphocytes
por: Kumari, Jaya, et al.
Publicado: (2013)

Type I interferons regulate eomesodermin expression and the development of unconventional memory CD8(+) T cells
por: Martinet, Valérie, et al.
Publicado: (2015)

Immune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacy
por: Adachi, Keishi, et al.
Publicado: (2015)

A humanized 4-1BB-targeting agonistic antibody exerts potent antitumor activity in colorectal cancer without systemic toxicity
por: Cheng, Lian-sheng, et al.
Publicado: (2022)

Novel Cancer Immunotherapies and Antitumor Immunity
por: Zhao, Lei, et al.
Publicado: (2019)

Addition of TLR9 agonist immunotherapy to radiation improves systemic antitumor activity
por: Younes, Ahmed I., et al.
Publicado: (2020)

SPS collider mode timing requirements for BB4 and BB5 experimental areas
por: Beetham, G
Publicado: (1980)

IRF4 Regulates the Ratio of T-Bet to Eomesodermin in CD8(+) T Cells Responding to Persistent LCMV Infection
por: Nayar, Ribhu, et al.
Publicado: (2015)

mTOR Modulates Lymphocyte Differentiation through T-bet and Eomesodermin in Response to Invasive Pulmonary Aspergillosis in Rats
por: Cui, Na, et al.
Publicado: (2016)

Expression of T-Bet, Eomesodermin, and GATA-3 Correlates With Distinct Phenotypes and Functional Properties in Porcine γδ T Cells
por: Rodríguez-Gómez, Irene M., et al.
Publicado: (2019)

Eomesodermin in CD4(+)T cells is essential for Ginkgolide K ameliorating disease progression in experimental autoimmune encephalomyelitis
por: Chen, Sheng, et al.
Publicado: (2021)

Evaluating the Cellular Targets of Anti-4-1BB Agonist Antibody during Immunotherapy of a Pre-Established Tumor in Mice
por: Lin, Gloria H. Y., et al.
Publicado: (2010)

Adjuvant for vaccine immunotherapy of cancer – focusing on Toll‐like receptor 2 and 3 agonists for safely enhancing antitumor immunity
por: Seya, Tsukasa, et al.
Publicado: (2015)

Creatine in T Cell Antitumor Immunity and Cancer Immunotherapy
por: Li, Bo, et al.
Publicado: (2021)

N-ras couples antigen receptor signaling to Eomesodermin and to functional CD8(+) T cell memory but not to effector differentiation
por: Iborra, Salvador, et al.
Publicado: (2013)

The T-box transcription factor Eomesodermin acts upstream of Mesp1 to specify cardiac mesoderm during mouse gastrulation
por: Costello, Ita, et al.
Publicado: (2011)

A Genomic Duplication is Associated with Ectopic Eomesodermin Expression in the Embryonic Chicken Comb and Two Duplex-comb Phenotypes
por: Dorshorst, Ben, et al.
Publicado: (2015)

Carcinoembryonic Antigen (CEA)-Specific 4-1BB-Costimulation Induced by CEA-Targeted 4-1BB-Agonistic Trimerbodies
por: Mikkelsen, Kasper, et al.
Publicado: (2019)

4-1BB agonism: adding the accelerator to cancer immunotherapy
por: Chester, Cariad, et al.
Publicado: (2016)

4-1BB: A promising target for cancer immunotherapy
por: Kim, Alyssa Min Jung, et al.
Publicado: (2022)

Tregs constrain CD8(+) T cell priming required for curative intratumorally anchored anti-4-1BB immunotherapy
por: Palmeri, Joseph R., et al.
Publicado: (2023)

Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade
por: Lee, Won Suk, et al.
Publicado: (2022)

Defining the role of the tumor vasculature in antitumor immunity and immunotherapy
por: Schaaf, Marco B., et al.
Publicado: (2018)

Epigenetic modulation of antitumor immunity for improved cancer immunotherapy
por: Dai, Enyong, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_aimu34qkh4psm77rinqfide127